|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.60 USD | +0.39% |
|
-5.19% | -3.15% |
| 11:01pm | AbbVie plans to build out its presence in obesity market | RE |
| 09:35pm | AbbVie Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 08:15 AM |
| Capitalization | 390B 335B 312B 290B 541B 35,221B 584B 3,584B 1,410B 16,848B 1,463B 1,433B 61,737B | P/E ratio 2025 * |
74.8x | P/E ratio 2026 * | 21.9x |
|---|---|---|---|---|---|
| Enterprise value | 446B 383B 357B 332B 619B 40,282B 667B 4,099B 1,612B 19,269B 1,673B 1,639B 70,608B | EV / Sales 2025 * |
7.32x | EV / Sales 2026 * | 6.55x |
| Free-Float |
96.39% | Yield 2025 * |
2.96% | Yield 2026 * | 3.09% |
Last Transcript: AbbVie Inc.
| 1 day | +0.43% | ||
| 1 week | -5.19% | ||
| Current month | -3.15% | ||
| 1 month | -2.70% | ||
| 3 months | -3.42% | ||
| 6 months | +15.55% | ||
| Current year | -3.15% |
| 1 week | 215.85 |  | 231.54 |
| 1 month | 215.85 | | 237.04 |
| Current year | 215.85 | | 237.04 |
| 1 year | 164.39 | | 244.81 |
| 3 years | 130.96 | | 244.81 |
| 5 years | 101.81 | | 244.81 |
| 10 years | 51.6 | | 244.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 23/06/2022 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2003 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 74 | 01/01/2013 |
Edward Rapp
BRD | Director/Board Member | 68 | 01/01/2013 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 7.12% | 6 M€ | |
| +1.23% | 6.85% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.40% | -5.19% | +26.06% | +44.80% | 390B | |
| -0.54% | -3.30% | +43.84% | +199.51% | 964B | |
| +2.33% | +5.30% | +50.95% | +26.77% | 515B | |
| +0.94% | +1.74% | +30.64% | +16.80% | 363B | |
| +2.41% | +2.19% | +32.56% | +23.08% | 292B | |
| +2.13% | +2.17% | +28.80% | +34.61% | 272B | |
| +2.44% | +1.80% | +10.94% | +0.09% | 269B | |
| -1.32% | +3.23% | -36.14% | -20.59% | 265B | |
| +0.98% | -4.17% | +22.58% | +21.52% | 175B | |
| +1.68% | -0.61% | +35.81% | +44.70% | 151B | |
| Average | +1.07% | +1.24% | +24.60% | +39.13% | 365.61B | |
| Weighted average by Cap. | +0.82% | +1.51% | +30.04% | +68.65% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 60.93B 52.29B 48.68B 45.3B 84.54B 5,501B 91.14B 560B 220B 2,631B 229B 224B 9,642B | 66.71B 57.25B 53.3B 49.6B 92.56B 6,023B 99.78B 613B 241B 2,881B 250B 245B 10,557B |
| Net income | 5.53B 4.74B 4.42B 4.11B 7.67B 499B 8.27B 50.79B 19.98B 239B 20.74B 20.31B 875B | 17.44B 14.97B 13.94B 12.97B 24.2B 1,575B 26.09B 160B 63.03B 753B 65.41B 64.06B 2,760B |
| Net Debt | 56.06B 48.11B 44.79B 41.68B 77.78B 5,061B 83.85B 515B 203B 2,421B 210B 206B 8,871B | 46.66B 40.04B 37.28B 34.69B 64.74B 4,212B 69.79B 429B 169B 2,015B 175B 171B 7,384B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 221.30 $ | +0.25% | 4,345,854 |
| 13/01/26 | 220.75 $ | +0.32% | 4,872,602 |
| 12/01/26 | 220.04 $ | -0.02% | 6,546,141 |
| 09/01/26 | 220.08 $ | -1.81% | 6,714,160 |
| 08/01/26 | 224.13 $ | -3.98% | 9,365,855 |
Delayed Quote Nyse, January 15, 2026 at 12:15 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition